NASDAQ:ALEC - Nasdaq - US0144421072 - Common Stock - Currency: USD
1.87
+0.01 (+0.54%)
The current stock price of ALEC is 1.87 USD. In the past month the price increased by 3.31%. In the past year, price decreased by -70.83%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. The company is headquartered in South San Francisco, California and currently employs 241 full-time employees. The company went IPO on 2019-02-07. The firm is focused on immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration diseases. The firm is engaged in developing therapies designed to counteract these pathologies simultaneously by restoring healthy immune function to the brain. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration and immunology to identify immune system. Its product candidates: latozinemab (AL001), AL002, and AL101, are in clinical development. Its immune-neurology product candidates are supported by biomarkers and seek to treat indications, including Alzheimer’s disease and genetically defined frontotemporal dementia patient populations. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients.
ALECTOR INC
131 Oyster Point Blvd., Suite 600
South San Francisco CALIFORNIA 94080 US
CEO: Arnon Rosenthal
Employees: 245
Company Website: https://alector.com
Investor Relations: https://investors.alector.com/
Phone: 14152315660
The current stock price of ALEC is 1.87 USD. The price increased by 0.54% in the last trading session.
The exchange symbol of ALECTOR INC is ALEC and it is listed on the Nasdaq exchange.
ALEC stock is listed on the Nasdaq exchange.
15 analysts have analysed ALEC and the average price target is 4.93 USD. This implies a price increase of 163.63% is expected in the next year compared to the current price of 1.87. Check the ALECTOR INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ALECTOR INC (ALEC) has a market capitalization of 183.13M USD. This makes ALEC a Micro Cap stock.
ALECTOR INC (ALEC) currently has 245 employees.
ALECTOR INC (ALEC) has a support level at 1.65 and a resistance level at 1.88. Check the full technical report for a detailed analysis of ALEC support and resistance levels.
The Revenue of ALECTOR INC (ALEC) is expected to decline by -31.32% in the next year. Check the estimates tab for more information on the ALEC EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ALEC does not pay a dividend.
ALECTOR INC (ALEC) will report earnings on 2025-02-26, after the market close.
ALECTOR INC (ALEC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.7).
The outstanding short interest for ALECTOR INC (ALEC) is 6.43% of its float. Check the ownership tab for more information on the ALEC short interest.
ChartMill assigns a technical rating of 1 / 10 to ALEC. When comparing the yearly performance of all stocks, ALEC is a bad performer in the overall market: 97.81% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to ALEC. ALEC scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months ALEC reported a non-GAAP Earnings per Share(EPS) of -1.7. The EPS decreased by -0.59% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -30.7% | ||
ROE | -133.19% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 77% to ALEC. The Buy consensus is the average rating of analysts ratings from 15 analysts.
For the next year, analysts expect an EPS growth of -22.77% and a revenue growth -31.32% for ALEC